Proteasome Inhibitors against Glioblastoma—Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine
Proteasome inhibitors are moieties targeting the proteolytic activity of a proteasome, with demonstrated efficacy in certain hematological malignancies and candidate drugs in other types of cancer, including glioblastoma (GBM). They disturb the levels of proteasome-regulated proteins and lead to the...
Main Author: | Agata Gozdz |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-11-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/30/11/702 |
Similar Items
-
Proteasome inhibitors: situation and prospects (literature review and own data)
by: A. A. Rukavitsyn, et al.
Published: (2016-10-01) -
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
by: Marta Pelon, et al.
Published: (2024-03-01) -
The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
by: Michael A. Harris, et al.
Published: (2020-05-01) -
Proteasome Inhibitors for the Treatment of Multiple Myeloma
by: Shigeki Ito
Published: (2020-01-01) -
New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)